BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27276736)

  • 1. Clinical Significance of Bone Marrow Involvement as Confirmed by Bone Marrow Aspiration vs. Bone Marrow Biopsy in Diffuse Large B-cell Lymphoma.
    Hantaweepant C; Chinthammitr Y; Khuhapinant A; Sukpanichnant S
    J Med Assoc Thai; 2016 Mar; 99(3):262-9. PubMed ID: 27276736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.
    Wolach O; Fraser A; Luchiansky M; Shapiro C; Radnay J; Shpilberg O; Lishner M; Lahav M
    Hematol Oncol; 2015 Mar; 33(1):42-7. PubMed ID: 24470400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index.
    Chung R; Lai R; Wei P; Lee J; Hanson J; Belch AR; Turner AR; Reiman T
    Blood; 2007 Aug; 110(4):1278-82. PubMed ID: 17475910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement.
    Jackson AE; Smeltzer JP; Habermann TM; Jones JM; Burnette B; Ristow K; Wiseman GA; Macon WR; Nowakowski GS; Witzig TE
    Am J Hematol; 2014 Sep; 89(9):865-7. PubMed ID: 24823914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Utility and prognostic value of PET/CT, bone marrow biopsy and aspirate for detection of bone marrow involvement in diffuse large B-cell lymphoma].
    Jiang XY; Zou DM; Zhang YQ; Wang Z; Zhang W; Zhou DB; Zhang Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):663-667. PubMed ID: 36709151
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma.
    Liang JH; Sun J; Wang L; Fan L; Chen YY; Qu XY; Li TN; Li JY; Xu W
    Oncotarget; 2016 Apr; 7(14):19072-80. PubMed ID: 26919239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.
    Kim JS; Gang GW; Lee SR; Sung HJ; Park Y; Kim DS; Choi CW; Kim BS
    Jpn J Clin Oncol; 2015 Oct; 45(10):914-20. PubMed ID: 26185139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
    Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS
    Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL).
    Mitterbauer-Hohendanner G; Mannhalter C; Winkler K; Mitterbauer M; Skrabs C; Chott A; Simonitsch-Klupp I; Gleiss A; Lechner K; Jaeger U
    Leukemia; 2004 Jun; 18(6):1102-7. PubMed ID: 15085149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.
    Chigrinova E; Mian M; Scandurra M; Greiner TC; Chan WC; Vose JM; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Tucci A; Facchetti F; Lazure T; Lambotte O; Montes-Moreno S; Piris MA; Nomdedeu JF; Uccella S; Rancoita PM; Kwee I; Zucca E; Bertoni F
    Hematol Oncol; 2011 Mar; 29(1):38-41. PubMed ID: 20635329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma.
    Hong J; Lee Y; Park Y; Kim SG; Hwang KH; Park SH; Jeong J; Kim KH; Ahn JY; Park S; Park J; Lee JH
    Ann Hematol; 2012 May; 91(5):687-695. PubMed ID: 22008868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma.
    Cerci JJ; Györke T; Fanti S; Paez D; Meneghetti JC; Redondo F; Celli M; Auewarakul C; Rangarajan V; Gujral S; Gorospe C; Campo MV; Chung JK; Morris TP; Dondi M; Carr R;
    J Nucl Med; 2014 Oct; 55(10):1591-7. PubMed ID: 25214642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
    Yao Z; Deng L; Xu-Monette ZY; Manyam GC; Jain P; Tzankov A; Visco C; Bhagat G; Wang J; Dybkaer K; Tam W; Hsi ED; van Krieken JH; Ponzoni M; Ferreri AJM; Møller MB; Winter JN; Piris MA; Fayad L; Liu Y; Song Y; Orlowski RZ; Kantarjian H; Medeiros LJ; Li Y; Cortes J; Young KH
    Leukemia; 2018 Feb; 32(2):353-363. PubMed ID: 28745330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow biopsy in adult acute lymphoblastic leukemia: morphological characteristics and contribution to the study of prognostic factors.
    Thomas X; Le QH; Danaïla C; Lhéritier V; Ffrench M
    Leuk Res; 2002 Oct; 26(10):909-18. PubMed ID: 12163052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.